Aurinia Pharmaceuticals vs Iovance Biotherapeutics
Aurinia Pharmaceuticals and Iovance Biotherapeutics are similar in size: $283m and $264m of revenue in their latest fiscal years. Iovance Biotherapeutics grew faster (60.6% against 20.4%). Aurinia Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 101.5% against -148.4%.
| Latest fiscal year | Aurinia PharmaceuticalsAUPH, 2025 | Iovance BiotherapeuticsIOVA, 2025 |
|---|---|---|
| Revenue | $283m | $264m |
| Revenue growth | 20.4% | 60.6% |
| Net income | $287m | −$391m |
| Operating margin | 37.1% | — |
| Net margin | 101.5% | -148.4% |
| Return on equity | 59.9% | -55.5% |
| Free cash flow | — | −$336m |
| Cash | $80.2m | $163m |
| Total debt | $0 | — |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $98.2m | — |
| Employees | 128 | 975 |
| Market value | $2.23bn | $3.95bn |
| Price vs our value range | Below our value range | — |
| Moat score | 32 (Weak) | — |
| Insider trades, 12 months | 11 buys, 2 sales | 0 buys, 0 sales |